The complete package of quality assurance solutions designed to ensure the accuracy and precision of tests and testing processes
NRL sets the global standard for a range of comprehensive External Quality Assessment Schemes (EQAS), Quality Control (QC) and Specificity Monitoring programs for a range of infectious diseases.
NRL Quality Assurance Brochure - (click to download and print)
For further information regarding any NRL Quality Assurance programs or for information regarding your local distributor, please contact firstname.lastname@example.org.
Click on one of the program names below to read further information.
NRL EQAS assess the integrity of the entire testing process by assessing laboratories' testing processes and test kits used, and identifying and resolving testing problems. Laboratories around the world join NRL EQAS through the DigitalPT International EQA Collaboration.
NRL EQAS participants receive panels that consist of a combination of positive and negative samples that would typically be received in a testing laboratory. They may include low positive samples or samples of varying genotypes or subtypes to challenge assay sensitivity.
Our extensive experience and scientific methodology are applied to the design and analysis of every NRL EQAS. Compare the EQAS from your current provider with NRL EQAS:
Further information regarding NRL EQAS can be found in the current NRL EQAS Catalogue. To order NRL EQAS, simply download, complete and return the NRL EQAS Order Form.
Quality Control for Molecular Diagnostics (QCMD; Glasgow, Scotland) is a leading provider of External Quality Assessment Schemes (EQAS) for clinical molecular diagnostic laboratories testing for infectious diseases. From 2012, NRL is pleased to be able to facilitate Australian laboratories’ participation in QCMD EQAS. NRL will act as a distribution hub for Australian laboratories. In this way, the cost of shipping from Scotland will be reduced. QCMD conducts over 60 different EQAS and provide these services to more than 6,000 laboratories world-wide, ensuring large peer groups for each program. Through this collaboration, NRL and QCMD seek to offer an extended range of EQAS to molecular testing laboratories.
We encourage laboratories to review the range of EQAS available on the QCMD website (www.qcmd.org). Orders should be placed directly on the website.
For further information please contact email@example.com.
NRL QC is a daily monitoring tool to ensure the accuracy and precision of test results. Using NRL’s EDCNet, laboratories can analyse and assess the variation in their test kits in real time, providing an independent mechanism to assure that test results are reliable.
Participants receive low positive QC samples that are customised to the specific test kit. The QC samples are tested as an external control in addition to, and not in place of, the controls provided by the test kit manufacturer.
The NRL QC advantage:
NRL QC is available for:
NRL QC specifically designed for blood screening laboratories:
To join NRL QC, simply download, complete and return the EDCNet Registration Form and Terms & Conditions.
NRL Specificity Monitoring is a program designed specifically for blood screening laboratories. By monitoring the rate of false reactivity (specificity) of a test kit, blood wastage is reduced to ensure adequate blood supply.
Blood screening laboratories testing for HIV, HCV, HBV and HTLV collate the number of specimens screened each week, test kit and batch information, the number of initially and repeatedly reactive specimens, and the number of confirmed positive samples. These data are submitted to NRL via EDCNet. The initial reactor rate (IRR) and repeat reactor rate (RRR) are calculated. The difference between the IRR and RRR is a measure of the overall laboratory or technical error. This may be calculated for the overall results, for given test kits and even for individual batches of any test kit.
NRL Specificity Monitoring identifies problematic batches of test kits and problems within a laboratory’s testing system. For assays that are used for large numbers of samples, e.g. blood donor testing, the rate of false reactivity (specificity) of a test kit can be monitored. False reactivity in blood screening test kits are usually very small (<1%). However, the accumulated data can be used to assess a test kit's ongoing performance and highlight changes which could have both financial and operational impact.
EDCNet Registration Form
EDCNet Terms & Conditions
EQAS 2013 Catalogue
EQAS 2013 Order Form